Kroemer G, Chan TA, Eggermont AMM, Galluzzi L.
2024.
Immunosurveillance in clinical cancer management.. CA Cancer J Clin. 74(2):187-202.
Wolujewicz P, Aguiar-Pulido V, Thareja G, Suhre K, Elemento O, Finnell RH, M Ross E.
2024.
Integrative computational analyses implicate regulatory genomic elements contributing to spina bifida.. Genet Med Open. 2:101894.
Nguyen DD, Hooper WF, Liu W, Chu TR, Geiger H, Shelton JM, Shah M, Goldstein ZR, Winterkorn L, Helland A et al..
2024.
The interplay of mutagenesis and ecDNA shapes urothelial cancer evolution.. Nature. 635(8037):219-228.
Vivelo C, Reilly KM, Widemann BC, Wedekind MFrances, Painter C, O'Neill AF, Mueller S, Elemento O, Gross AM, Sandler AB.
2024.
The Landscape of US and Global Rare Tumor Research Programs: A Systematic Review.. Oncologist. 29(2):106-116.
Li X-Q, Yamazaki T, He T, Alam MMasud, Liu J, Trivett AL, Sveinbjørnsson B, Rekdal Ø, Galluzzi L, Oppenheim JJ et al..
2024.
LTX-315 triggers anticancer immunity by inducing MyD88-dependent maturation of dendritic cells.. Front Immunol. 15:1332922.
Montrose DC, Saha S, Galluzzi L.
2024.
Metabolic regulation of the mitochondrial immune checkpoint.. Oncoimmunology. 13(1):2394247.
Guilbaud E, Galluzzi L.
2024.
A mitochondrial checkpoint to NF-κB signaling.. Cell Death Dis. 15(7):477.
Sumiyoshi T, Wang X, Warner EW, Sboner A, Annala M, Sigouros M, Beja K, Mizuno K, Ku S, Fazli L et al..
2024.
Molecular features of prostate cancer after neoadjuvant therapy in the phase 3 CALGB 90203 trial.. J Natl Cancer Inst. 116(1):115-126.